Anthem Biosciences Downgraded to Sell Amid Technical and Financial Weakness

Quality Assessment: Mixed Signals from Financial Performance

Anthem Biosciences continues to demonstrate strong management efficiency, with a return on equity (ROE) of 19.93%, indicating effective utilisation of shareholder capital. However, recent quarterly financial results have cast a shadow over the company’s quality rating. The third quarter of fiscal year 2025-26 saw a significant decline in profitability, with profit before tax (PBT) falling by 24.2% to ₹122.31 crores compared to the previous four-quarter average. Similarly, profit after tax (PAT) dropped by 14.1% to ₹110.87 crores, while net sales reached a low of ₹423.15 crores, marking a concerning downturn in revenue generation.

Despite these setbacks, Anthem Biosciences maintains a low debt-to-equity ratio averaging zero, underscoring a conservative capital structure that mitigates financial risk. Long-term growth trends remain healthy, with net sales growing at an annualised rate of 29.80% and operating profit expanding by 44.32%. This juxtaposition of strong historical growth and recent quarterly weakness contributes to a nuanced quality profile.

Valuation: Elevated Price-to-Book Ratio Raises Concerns

The company’s valuation has become increasingly expensive, with a price-to-book (P/B) ratio of 13.0, which is notably high for the Pharmaceuticals & Biotechnology sector. This elevated valuation suggests that the market has priced in significant growth expectations, which recent financial results have failed to meet. The return on equity of 17.7% further emphasises the premium investors are paying for Anthem Biosciences, despite the recent stagnation in stock price performance.

Over the past year, the stock has generated a flat return of 0.00%, contrasting with a 4.35% gain in the Sensex benchmark. While profits have risen by 35% over the same period, the lack of corresponding share price appreciation indicates a disconnect between earnings growth and market sentiment, likely contributing to the downgrade in valuation grade.

Financial Trend: Recent Quarter Undermines Positive Momentum

While Anthem Biosciences has exhibited robust long-term growth, the latest quarterly results have disrupted this positive trajectory. The Q3 FY25-26 performance revealed a sharp decline in key financial metrics, with net sales at their lowest level in recent quarters and profitability contracting significantly. This downturn has led to a reassessment of the company’s financial trend, which now reflects caution rather than confidence.

Despite the negative quarterly results, the company’s long-term fundamentals remain intact, supported by a strong operating profit growth rate of 44.32% and a debt-free balance sheet. However, the immediate financial trend downgrade signals potential headwinds that investors should monitor closely.

Technical Analysis: Shift from Mildly Bullish to Sideways

The technical outlook for Anthem Biosciences has deteriorated, prompting a downgrade in the technical grade. Previously characterised by a mildly bullish weekly MACD and Dow Theory signals, the technical trend has shifted to a sideways pattern. Key indicators such as the weekly Relative Strength Index (RSI) and On-Balance Volume (OBV) now show no clear trend, while Bollinger Bands on the weekly chart also reflect sideways movement.

Daily moving averages and monthly technical indicators fail to provide a definitive directional signal, further reinforcing the neutral technical stance. This sideways technical trend suggests a lack of momentum in the stock price, which closed at ₹660.00 on 10 March 2026, marginally down 0.16% from the previous close of ₹661.05. The stock’s 52-week range remains wide, with a high of ₹873.25 and a low of ₹579.45, indicating volatility but no sustained directional bias.

Comparative Performance: Underperforming Sensex Benchmarks

Anthem Biosciences’ recent returns have lagged behind the broader market. Over the past week, the stock declined by 3.88%, slightly worse than the Sensex’s 3.33% fall. Over one month, the stock’s loss of 1.95% contrasts with a more pronounced 7.73% decline in the Sensex, suggesting relative resilience in the short term. Year-to-date, Anthem Biosciences has posted a modest 1.37% gain, outperforming the Sensex’s negative 8.98% return.

Longer-term returns are unavailable for the stock, but the Sensex’s 10-year return of 212.84% highlights the broader market’s strong performance, underscoring the importance of Anthem Biosciences addressing its current challenges to align with sector and market growth.

Outlook and Investor Considerations

The downgrade of Anthem Biosciences Ltd to a Sell rating reflects a convergence of factors that have eroded investor confidence. The technical shift to a sideways trend indicates a lack of price momentum, while the disappointing quarterly financial results raise questions about near-term earnings stability. The company’s valuation remains stretched, with a high price-to-book ratio that may not be justified given the recent performance.

Nonetheless, Anthem Biosciences retains several strengths, including a strong ROE, low leverage, and solid long-term growth in sales and operating profit. Investors should weigh these positives against the current challenges and monitor upcoming quarterly results for signs of recovery or further deterioration.

Given the stock’s underperformance relative to the Sensex and the Pharmaceuticals & Biotechnology sector, cautious investors may prefer to reassess their exposure or consider alternative opportunities within the sector that offer more favourable technical and financial profiles.

Shareholding and Market Capitalisation

The company’s majority ownership remains with promoters, providing stability in governance. However, the market cap grade of 2 indicates a relatively modest market capitalisation, which may contribute to liquidity constraints and increased volatility. This factor, combined with the current technical and financial outlook, supports the cautious stance reflected in the Sell rating.

Summary of Ratings and Scores

As of 9 March 2026, Anthem Biosciences Ltd holds a Mojo Score of 40.0 and a Mojo Grade of Sell, downgraded from Hold. The market cap grade stands at 2. Technical indicators have shifted from mildly bullish to sideways, while financial trends have weakened due to recent quarterly results. Valuation remains expensive, and quality metrics present a mixed picture with strong ROE but declining quarterly profits.

Investors should remain vigilant and consider these factors carefully when making portfolio decisions involving Anthem Biosciences Ltd.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today